Background: Antidepressants and anxiolytics have demonstrated short-term efficacy; however, little is known about the long-term effectiveness of these drugs.
Aims: To investigate long-term psychiatric outcomes following antidepressant and/or anxiolytic use during an episode of mental disorder in mid-life.
Method: Members of the 1946 British birth cohort were assessed for symptoms of depression and anxiety at age 43. Among 157 with mental disorder, those using antidepressants and/or anxiolytics were compared with those not using medications on psychiatric outcomes at age 53.
Results: Use of antidepressants or anxiolytics was associated with a lower prevalence of mental disorder at age 53 (odds ratio (OR)=0.3, 95% CI 0.1-1.0) after adjustment for eight variables in a propensity-for-treatment analysis. Only 24% of those being treated with medications at age 43 were still using them at 53.
Conclusions: Use of antidepressants or anxiolytics during an episode of mental disorder may have long-term beneficial effects on mental health. This may be because of a demonstrated willingness to seek help rather than long-term maintenance therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1192/bjp.bp.107.043430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mental Health Utilization Among Transgender Veterans.
JAMA Netw Open
January 2025
VA Center for Health Information and Communication, US Department of Veterans Affairs, Veterans Health Administration, Health Systems Research CIN 13-416, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana.
Importance: Compared with cisgender (CG) individuals, transgender and gender-diverse (TGD) individuals experience substantial social and economic disparities that can result in adverse mental health consequences. It is critical to understand potential barriers to care and to address the causes of the disparities in the future.
Objective: To characterize mental health care utilization among TGD veterans with depression.
Therapeutic potential of trazodone in trigeminal neuralgia based on inflammation and oxidative stress: an experimental study.
J Oral Facial Pain Headache
June 2024
Department of Geriatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), 310003 Hangzhou, Zhejiang, China.
Trigeminal neuralgia (TN) is a debilitating condition affecting the patients' life quality. New therapeutic approaches and novel drugs are required to treat TN. Trazodone being a serotonin antagonist and reuptake inhibitor (SARI) provides neuroprotection, however its role and underlying mechanism in TN or are not clear.
View Article and Find Full Text PDFVarious topical drug combination assessed using a neurosensory stent for chronic intraoral neuropathic pain: a pilot study.
J Oral Facial Pain Headache
September 2024
Department of Pediatric Dentistry, Barzilai Medical Center, 7830604 Ashkelon, Israel.
Chronic intraoral neuropathic pain (NP), often developing post-dental procedures, poses significant management challenges. The prevalent use of systemic treatments, with their frequent substantial side effects, emphasizes the need for alternative therapeutic strategies. Our aim is to explore the efficacy and adherence with a topical drug regimen delivered through a neurosensory stent (NS) for treating chronic neuropathic pain (NP) within the oral cavity.
View Article and Find Full Text PDFPreclinical and in silico studies of 3-benzothioyl-1-(3-hydroxy-3-phenyl-3-propyl)-1-methylthiourea: a promising agent for depression and anxiety.
Eur J Pharmacol
January 2025
Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan-23200, Pakistan; Department of Pharmacy, Korea University, Sejong 20019, South Korea. Electronic address:
The study investigated the anxiolytic, antidepressant, sedative/hypnotic and in silico molecular docking properties of the synthetic ephedrine-based derivative of thiourea, 3-benzothioyl-1-(3-hydroxy-3-phenyl-3-propyl)-1-methylthiourea. Safety profile of the compound at various doses was determined in an acute toxicity test. Results showed significant anti-anxiety effects of the compound in all mice studies.
View Article and Find Full Text PDFCreation of Long-Term Physical Stability of Amorphous Solid Dispersions N-Butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, Resistant to Recrystallization Caused by Exposure to Moisture.
Materials (Basel)
January 2025
Institute of Pharmacy and Biotechnology, Peoples' Friendship University of Russia n.a. P. Lumumba (RUDN), 6 Miklukho-Maklaya Str., 117198 Moscow, Russia.
Amorphous solid dispersion (ASD) technology is often used as a promising strategy to improve the solubility of active pharmaceutical ingredients (APIs). ASDs allow APIs to be dispersed at the molecular level in a polymer carrier, destroying the crystalline structure of the APIs and, thanks to the polymer, providing long-term supersaturation in solution. However, stability issues are an obstacle to the development of new medications with ASD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!